Comments
Shares of Dr Reddy's Laboratories plunged as much as 2 per cent on Tuesday as US Food and Drug Administration (USFDA) has not yet ‘closed’ its inspection of the formulations unit of Dr Reddy’s Laboratories Ltd located at Duvvada in Visakhapatnam.
Following a weak open at Rs 2,375 against the previous close of Rs 2,390.85, the scrip touched an intraday high of 2,382.95 and a low of Rs 2,342. In terms of equity volume, 0.36 lakh shares were traded on the BSE.
The company shares ended down by 1.23 per cent at Rs 2,361.35.
In an update to the bourses on Tuesday, the Hyderabad-based Dr Reddy’s had said the company had received the Establishment Inspection Report (EIR) for the facility from the US regulator.
The USFDA had issued a warning letter to the drug major on November 5, 2015, regarding the Duvvada unit.
The company plans to request for a re-inspection of the facility in 2018 after further discussions on scheduling with the USFDA.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.